Axsome Therapeutics (STU:19X) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:19X Axsome Therapeutics Inc STU:19X
58 GF Score
Price €199.95
GF Value €196.69
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Axsome Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:19X
58GF Score
Axsome Therapeutics Inc STU:19X
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Axsome Therapeutics (STU:19X) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of €199.95 is trading 1.7% above its estimated GF Value™ of €196.69. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for STU:19X:

  • FFO:
  • GF Value™: €196.69 vs. price of €199.95 (1.7% above fair value)
  • GF Score™: 58/100 with 1 warning sign

No single metric tells the full story. See the STU:19X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Axsome Therapeutics Business Description

Other Exchanges AXSM:USA1AXSM:Italy0HKF:UK
Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
58GF Score

Get the complete analysis for STU:19X

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€199.95
Price
€196.69
GF Value